125 related articles for article (PubMed ID: 9222284)
1. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Morabito F; Callea I; Irrera G; Cartisano G; Dattola A; Rodinò A; Brugiatelli M
Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil in chronic lymphocytic leukemia: mechanism of action.
Begleiter A; Mowat M; Israels LG; Johnston JB
Leuk Lymphoma; 1996 Oct; 23(3-4):187-201. PubMed ID: 9031099
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia.
Kost SE; Bouchard ED; LaBossière É; Ye X; Queau ML; Liang WS; Banerji V; Gibson SB; Katyal S; Johnston JB
Leuk Res; 2016 Nov; 50():63-71. PubMed ID: 27683974
[TBL] [Abstract][Full Text] [Related]
6. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
7. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia.
Begleiter A; Wang H; Verburg L; Lee K; Israels LG; Mowat MR; Johnston JB
Leukemia; 1996 Dec; 10(12):1959-65. PubMed ID: 8946937
[TBL] [Abstract][Full Text] [Related]
8. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
Rizzato G; Riboldi A; Imbimbo B; Torresin A; Milani S
Respir Med; 1997 Sep; 91(8):449-60. PubMed ID: 9338047
[TBL] [Abstract][Full Text] [Related]
9. Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Callea I; Console G; Sculli G; Filangeri M; Messina G; Morabito F
Haematologica; 1998 Aug; 83(8):756-7. PubMed ID: 9793266
[TBL] [Abstract][Full Text] [Related]
10. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
Christodoulopoulos G; Malapetsa A; Schipper H; Golub E; Radding C; Panasci LC
Clin Cancer Res; 1999 Aug; 5(8):2178-84. PubMed ID: 10473103
[TBL] [Abstract][Full Text] [Related]
11. Imatinib sensitizes CLL lymphocytes to chlorambucil.
Aloyz R; Grzywacz K; Xu ZY; Loignon M; Alaoui-Jamali MA; Panasci L
Leukemia; 2004 Mar; 18(3):409-14. PubMed ID: 14712290
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
13. Potency ratio--a brief synopsis.
Avioli LV
Br J Rheumatol; 1993 May; 32 Suppl 2():24-6. PubMed ID: 8495276
[TBL] [Abstract][Full Text] [Related]
14. [In vivo study of spontaneous and therapy-induced apoptosis in patients with chronic lymphocytic leukemia treated with chlorambucil].
Marjanović S; Brajusković G; Skaro-Milić A; Malesević M
Vojnosanit Pregl; 1999; 56(4):377-82. PubMed ID: 10528523
[TBL] [Abstract][Full Text] [Related]
15. Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Morabito F; Callea I; Rodinò A; Messina G; Callea V; Iacopino P; Nobile F; Brugiatelli M
Leukemia; 1995 Sep; 9(9):1450-5. PubMed ID: 7658711
[TBL] [Abstract][Full Text] [Related]
16. Deflazacort induced stronger immunosuppression than expected.
Gonzalez-Castañeda RE; Castellanos-Alvarado EA; Flores-Marquez MR; Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
[TBL] [Abstract][Full Text] [Related]
17. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
Broyer M; Terzi F; Lehnert A; Gagnadoux MF; Guest G; Niaudet P
Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
[TBL] [Abstract][Full Text] [Related]
18. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.
Ganapati A; Ravindran R; David T; Yadav B; Jeyaseelan V; Jeyaseelan L; Danda D
Lupus; 2018 May; 27(6):890-898. PubMed ID: 29320974
[TBL] [Abstract][Full Text] [Related]
19. The effect of chlorambucil treatment on cytogenetic parameters in chronic lymphocytic leukemia patients.
Amiel A; Biton I; Yukla M; Gaber E; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2003 Jun; 143(2):113-9. PubMed ID: 12781444
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
Aicardi G; Benso L; Vignolo M; Terragna A; Verrina E; Cordone G; Coppo R; Sernia O; Sardella ML; Di Battista E
Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
